A list of 2017 China’s top 100 Pharmaceutical companies was released on July 3rd. GPHL ranked first on the list, claiming the top spot for seven consecutive years now. Due to rapid yet sustainable development in recent years, GPHL’s total sales revenue has exceed 100 billion yuan.

The ranking was determined by the Nanfang Medicine & Economy Research Institute and the Medicine Economic Reporter, a medical industry news provider. As both organizations are led by the China Food and Drug Administration, the list is considered as an official market indicator covering research institutes, pharmaceutical companies, hospitals and drugstores in China’s pharmaceutical industry.

Benefiting from Guangzhou’s efforts to develop IAB industries (information technology, artificial intelligence and bio-technology), GPHL has seized the day and has been focused on the R&D of antineoplastic drugs and vaccines. According to the company, 13 new types of these drugs are under research.

Last year, GPHL received permission from the China Food and Drug Administration to conduct clinical trials with Ceftriamidine Sodium and Ceftriamidine Sodium for Injection, a new drug to treat pneumonia. The drug is the only new class 1.1 cephalosporin drug to have gained this permit over the past two decades. It was also granted a US patent and two Chinese patents.

To boost its R&D ability, GPHL has formed a research team composed of 2 Nobel winners, 16 TCM academicians, and roughly 100 researchers with PhD degrees. It has also established 8 national labs and a series of technical centers.

The photo shows Li Chuyuan, Chairman of GPHL, giving a speech at the Fortune Global Forum. Apart from providing a wide range of products, GPHL participated in more international events, expanding its network into overseas markets.

Meanwhile, Wanglaoji, GPHL’s flagship product, continues to play an important role in the enterprise’s development. Since it’s launch 190 years ago, it has remained one of the most popular herbal tea brands in China, with a high sales volume.

In 2017, four ‘1828 Wanglaoji’ fresh brewed herbal tea stores opened for business in Zhujiang New Town, Guangzhou. The company is now dedicated to providing a space to enjoy a nice cup of freshly-brewed herbal tea.

According to GPHL, it maintained steady and rapid growth in the first quarter of 2018 with sales reaching 31.04 billion yuan (up 21.1 percent YoY) and profits reaching 1.462 billion yuan (up 63.78 precent YoY).

The operating revenue of BaiYunShan, a listed company under the GPHL umbrella, grew 30.66 percent YoY to 6.909 billion yuan. And the net profit of its shareholders increased 86.76 percent YoY to 905 million; a record high.

Reported by Jasmine Yin, Rebecca Tao

Edited by Olivia Ouyang, Simon Haywood